Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
FORT WORTH, Texas, Jan. 18 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today that it has engaged National Investment Banking firm Miller Tabak & Co., LLC, a twenty-eight year old institutional trading firm as part of its strategy in accelerating the search for potential partners that will help grow revenues, which are necessary to execute Wound Managements plans for 2010. According to Deborah Jenkins Hutchinson, Wound Management President, "We believe that partnering with Miller Tabak will be a key relationship to help us identify the partners that will benefit WMT the most and will help us to reach our strategic goals this year more quickly." The agreement is performance based.
Since 1982, Miller Tabak has gained tremendous experience and expertise in stocks and options transactions as well as creating a vast network using electronic markets and information sources. Today, MT has the most advanced technology systems available helping to create proprietary expert strategies, providing clients with split second accuracy and opportune reactions to market conditions. Offices in New York, Boston, and San Diego provide them with a country-wide footprint from which to operate.
For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM - News), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene http://www.celgene.com, Geron http://www.geron.com, and Human Genome Sciences http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications 954-357-0614
SOURCE Wound Management Technologies, Inc.
You May Also Like